TransMedics
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| TransMedics (TMDX) | 2.96B | 23.23 | 5.38 | 0.00% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 17.8% below Morningstar's fair value estimate.
Fair value
TransMedics Group Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $100.40 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's solid growth bolsters our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 52.3% lies in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.
On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 18.0%, a core component of valuation, lies in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
TransMedics discussion 0 comments